MIPS researcher receives grant from MS Research Australia
Professor Jonathan Baell from the Medicinal Chemistry theme of the Monash Institute of Pharmaceutical Sciences (MIPS) has been awarded a Project Grant from MS Research Australia to develop a new test to monitor multiple sclerosis (MS) disease
Monash Institute of Pharmaceutical Sciences receives MRFF funding for COVID-19 vaccine Phase 1 clinical trial
The Commonwealth Government’s Medical Research Future Fund (MRFF) has invested just over $1.5 million to begin the Phase 1 clinical trial of two Melbourne-based COVID-19 vaccine candidates.
Iconovo signs agreement for development of inhaled oxytocin in ICOone® for maternal health
Lund, December 22, 2020. Iconovo AB (publ) today announced that the company has signed a development agreement with Monash University for the development of inhaled oxytocin
Researchers identify off switch for alcoholism
Researchers from Monash University and the Florey Institute have made a potential breakthrough in the ability to treat alcohol addiction with a simple drug.
2020 NHMRC Ideas Grant: MIPS researchers awarded over $2 million to progress research into treatments for neurodegenerative disorders and breast cancer
Two scientists from the Monash Institute of Pharmaceutical Sciences (MIPS) have been awarded 2020 National Health and Medical Research Council (NHMRC) Ideas Grants, worth more than $2 million combined.
Magic Milk: Monash University paves the way for infant substitutes and nutrition
Digestion specialist, Dr Andrew Clulow, from the Monash Institute of Pharmaceutical Sciences (MIPS) is continuing to break ground in the world of milk and infant nutrition discoveries with a new study that has shown that mixing cow milk fat with
ARC Linkage grant extends successful collaboration between MIPS and Starpharma
A long running collaboration between scientists at the Monash Institute of Pharmaceutical Sciences (MIPS) and Melbourne-based biotechnology company Starpharma has been awarded $433,000 through the ARC linkage scheme.
Uptake of highly effective female contraception is lower in Victoria and New South Wales compared to other states
A new nationwide study led by Monash University has found that the rate of supply for hormonal long-acting reversible contraception (LARC) in Australia began to plateau from 2015.